Reid Hoffman Leaves Microsoft Board to Launch AI Startup Manus

TL;DR

• Reid Hoffman is stepping down from Microsoft’s board after nearly a decade, saying he wants to return to “founder mode” and focus on his AI drug-discovery startup, Manas AI.
• Microsoft says Hoffman’s departure is not tied to any disagreement with management; he will remain on the board until the company’s annual meeting later this year.
• Manas AI is positioning itself as an AI-native biopharmaceutical company aimed at accelerating cancer drug discovery, with more than $50 million raised across seed rounds and Siddhartha Mukherjee as CEO.

Hoffman exits after nearly a decade at Microsoft

Reid Hoffman, the LinkedIn co-founder and longtime investor, is leaving Microsoft’s board after almost ten years of service. Microsoft said he chose not to seek reelection and will remain a director until the company’s annual meeting later this year.

Hoffman joined Microsoft’s board in 2017, shortly after the company completed its $26.2 billion acquisition of LinkedIn. His tenure overlapped with a period of major strategic change for Microsoft, including its expanded focus on cloud, AI, and enterprise software.

Why Hoffman is stepping away

Hoffman has said the move is about concentrating on his startup, Manas AI, which he described as reaching a point where he needs to return to “founder mode.” On his “Possible” podcast with Microsoft CEO Satya Nadella, he said he wanted to devote more attention to the company’s progress.

Microsoft stressed that the decision was not caused by any disagreement over the company’s operations, policies, or practices. That matters because board departures can sometimes signal conflict, but in this case the company publicly framed the move as amicable.

What Manas AI is building

Manas AI is a drug-discovery startup focused on using artificial intelligence to speed up the development of cancer therapies. The company has said it is targeting difficult cancers such as prostate cancer, lymphoma, and triple-negative breast cancer.

The startup’s approach combines AI-driven filtering with chemical libraries to identify promising drug candidates faster than traditional discovery pipelines. Hoffman has described the effort as a push toward “Move 37” AI, a reference to AI that can go beyond human creativity in chemistry and help generate new therapeutic possibilities.

The people behind the startup

Hoffman is listed as a co-founder and chairman of Manas AI, while the CEO role belongs to Dr. Siddhartha Mukherjee. Mukherjee is a physician, biologist, and Pulitzer Prize-winning author best known for The Emperor of All Maladies.

The company also has support from investors including General Catalyst and Greylock, and Hoffman has been a visible public face for the startup since its launch. CNBC reported that Manas raised about $24.6 million in seed funding, while TechCrunch said the total from seed rounds last year topped $50 million.

Why this matters for AI and biotech

Hoffman’s move underscores how quickly top tech investors are shifting from broad AI bets into specialized verticals like biotech. Drug discovery is one of the most closely watched applications of AI because even small efficiency gains can save years of research and large sums of money.

If Manas can translate AI models into real drug candidates, it could become an important player in the next wave of biotech startups. But the sector is notoriously difficult: promising computational results must still survive laboratory testing, clinical trials, and regulatory review.

A broader pattern in Hoffman’s career

Hoffman has repeatedly stepped away from governance roles when they begin to conflict with his growing AI investments. He left OpenAI’s board in 2023, citing the need to avoid potential conflicts of interest as he backed more AI companies.

That history suggests his Microsoft departure is less an exit from big tech than a reallocation of attention toward startup building. In Hoffman’s case, the phrase “founder mode” is not just a slogan; it marks a return to hands-on company creation after years as a board member and investor.

What to watch next

The main questions now are whether Hoffman’s departure changes anything at Microsoft and whether Manas can turn its early momentum into clinical progress. For Microsoft, the transition appears orderly, with no sign of friction and no immediate disruption reported.

For Manas, the challenge is much bigger: proving that AI can materially improve drug discovery in a field where timelines are long and failure rates are high. If the company succeeds, Hoffman’s shift from Microsoft board member to biotech founder could become one of the more notable pivots in the current AI boom.

AndroGuider Team

Articles written by the AndroGuider team. We try to make them thorough and informational while being easy to read.